 Biogen NASDAQ: BIIB shares slid 12.9 in June, according to data provided by SP; Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis MS drug. In a challenge involving rival Mylan, a federal court in West Virginia invalidated Biogens Tecfidera patent. The decision clears the way for rival Mylan to bring a generic competitor to market. 